Precision genetic medicine enlists antisense oligonucleotides (ASOs) to bind to nucleic acid targets important for human disease. Peptide nucleic acids (PNAs) have many desirable attributes as ASOs but lack cellular permeability. Here, we use an assay based on the corrective splicing of an mRNA to assess the ability of synthetic peptides to deliver a functional PNA into a human cell. We find that the endosomolytic peptides L17E and L17ER are highly efficacious delivery vehicles. Co-treatment of a PNA with low micromolar L17E or L17ER enables robust corrective splicing in nearly all treated cells. Peptide-PNA conjugates are even more effective. These results enhance the utility of PNAs as research tools and potential therapeutic agents.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213006 | PMC |
| http://dx.doi.org/10.1101/2024.06.18.599558 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endosomolytic peptides enable the cellular delivery of peptide nucleic acids.
Chem Commun (Camb)
December 2024
Department of Chemistry, Massachusetts institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
Precision genetic medicine enlists antisense oligonucleotides (ASOs) to bind to nucleic acid targets important for human disease. Peptide nucleic acids (PNAs) have many desirable attributes as ASOs but lack cellular permeability. Here, we use an assay based on the corrective splicing of an mRNA to assess the ability of synthetic peptides to deliver a functional PNA into a human cell.
View Article and Find Full Text PDFAnti-IL-1RAP scFv-mSA-S19-TAT fusion carrier as a multifunctional platform for versatile delivery of biotinylated payloads to myeloid leukemia cells.
Sci Rep
October 2024
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Article Synopsis
- Acute myeloid leukemia (AML) is a complex and aggressive form of blood cancer, characterized by various subgroups that complicate treatment development.
- Researchers have engineered two multifunctional fusion proteins to deliver targeted anti-cancer therapies specifically to leukemia cells by combining several components that enhance cell uptake and delivery.
- Initial testing shows promise for these proteins, demonstrating effective binding, cellular absorption, and the ability to enter the nucleus without harming normal cells, suggesting potential for improved cancer treatment methods.
Precision genetic medicine enlists antisense oligonucleotides (ASOs) to bind to nucleic acid targets important for human disease. Peptide nucleic acids (PNAs) have many desirable attributes as ASOs but lack cellular permeability. Here, we use an assay based on the corrective splicing of an mRNA to assess the ability of synthetic peptides to deliver a functional PNA into a human cell.
View Article and Find Full Text PDFEvaluation of the Cytosolic Uptake of HaloTag Using a pH-Sensitive Dye.
ACS Chem Biol
April 2024
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.
The efficient cytosolic delivery of proteins is critical for advancing novel therapeutic strategies. Current delivery methods are severely limited by endosomal entrapment, and detection methods lack sophistication in tracking the fate of delivered protein cargo. HaloTag, a commonly used protein in chemical biology and a challenging delivery target, is an exceptional model system for understanding and exploiting cellular delivery.
View Article and Find Full Text PDFA Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
ACS Nano
March 2024
Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235, United States.
Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete and durable responses, but only for a minority of patients. Resistance to ICB can largely be attributed to insufficient number and/or function of antitumor CD8 T cells in the tumor microenvironment. Neoantigen targeted cancer vaccines can activate and expand the antitumor T cell repertoire, but historically, clinical responses have been poor because immunity against peptide antigens is typically weak, resulting in insufficient activation of CD8 cytotoxic T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!